| Reference |
|---|
Luo Y, Zhang Z, Ren J, Dou C, Wen J, Yang Y, et al. SARS-Cov-2 spike induces intestinal barrier dysfunction through the interaction between CEACAM5 and Galectin-9. Front Immunol. 2024;15:1303356 pubmed publisher |
Chen X, Zhao J, Yue S, Li Z, Duan X, Lin Y, et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat Cancer. 2024;: pubmed publisher |
Quaranta P, Scabia G, Storti B, Dattilo A, Quintino L, Perrera P, et al. SARS-CoV-2 Infection Alters the Phenotype and Gene Expression of Adipocytes. Int J Mol Sci. 2024;25: pubmed publisher |
Di Primio C, Quaranta P, Mignanelli M, Siano G, Bimbati M, Scarlatti A, et al. Severe acute respiratory syndrome coronavirus 2 infection leads to Tau pathological signature in neurons. PNAS Nexus. 2023;2:pgad282 pubmed publisher |
Zheng J, Zheng Z, Fu C, Weng Y, He A, Ye X, et al. Deciphering intercellular signaling complexes by interaction-guided chemical proteomics. Nat Commun. 2023;14:4138 pubmed publisher |
Addetia A, Piccoli L, Case J, Park Y, Beltramello M, Guarino B, et al. Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants. bioRxiv. 2023;: pubmed publisher |
Marzi R, Bassi J, Silacci Fregni C, Bartha I, Muoio F, Culap K, et al. Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. iScience. 2023;26:105726 pubmed publisher |
Li M, Zhang Y, Zeb A, Wu Y, Cheng L. Bergamottin and PAP-1 Induced ACE2 Degradation to Alleviate Infection of SARS-CoV-2. Int J Mol Sci. 2022;23: pubmed publisher |
Kotani N, Nakano T, Kuwahara R. Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis. J Biol Chem. 2022;298:102500 pubmed publisher |
Li T, Soelberg S, Taylor Z, Sakthivelpathi V, Furlong C, Kim J, et al. Highly Sensitive Immunoresistive Sensor for Point-Of-Care Screening for COVID-19. Biosensors (Basel). 2022;12: pubmed publisher |
Walter J, Scherer M, Hutter C, Garaeva A, Zimmermann I, Wyss M, et al. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance. EMBO Rep. 2022;23:e54199 pubmed publisher |
Bassi J, Giannini O, Silacci Fregni C, Pertusini L, Hitz P, Terrot T, et al. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE. 2022;17:e0263328 pubmed publisher |
Duan X, Shi Y, Zhang X, Ge X, Fan R, Guo J, et al. Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody. Biosens Bioelectron. 2022;199:113883 pubmed publisher |
Liu H, Shi J, Fok K, Chen H. The N501Y Mutation of SARS-CoV-2 Spike Protein Impairs Spindle Assembly in Mouse Oocytes. Reprod Sci. 2022;29:2842-2846 pubmed publisher |
Ahmad M, Mustafa F, Panicker N, Rizvi T. Optical Detection of SARS-CoV-2 Utilizing Antigen-Antibody Binding Interactions. Sensors (Basel). 2021;21: pubmed publisher |
Schepens B, van Schie L, Nerinckx W, Roose K, Van Breedam W, Fijalkowska D, et al. An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. Sci Transl Med. 2021;13:eabi7826 pubmed publisher |
Nie J, Xie J, Liu S, Wu J, Liu C, Li J, et al. Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants. Cell Discov. 2021;7:53 pubmed publisher |
Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat Commun. 2021;12:2623 pubmed publisher |
Asarnow D, Wang B, Lee W, Hu Y, Huang C, Faust B, et al. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. Cell. 2021;184:3192-3204.e16 pubmed publisher |
Haymond A, Damluji A, Narayanan A, Mueller C, Reeder A, Alem F, et al. Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days. J Infect Dis. 2021;223:1677-1680 pubmed publisher |
Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577 pubmed publisher |
Shi Y, Shi J, Sun L, Tan Y, Wang G, Guo F, et al. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins. J Virol. 2021;: pubmed publisher |
Zhu Z, Qiu X, Wu S, Liu Y, Zhao T, Sun Z, et al. Blocking Effect of Demethylzeylasteral on the Interaction between Human ACE2 Protein and SARS-CoV-2 RBD Protein Discovered Using SPR Technology. Molecules. 2020;26: pubmed publisher |
Haun B, Lai C, Williams C, Wong T, Lieberman M, Pessaint L, et al. CoVaccine HT™ Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization. Front Immunol. 2020;11:599587 pubmed publisher |
Piccoli L, Park Y, Tortorici M, Czudnochowski N, Walls A, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183:1024-1042.e21 pubmed publisher |
Huang P, Tsai H, Liao B, Lin Y, Jan J, Tao M, et al. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain. Hum Vaccin Immunother. 2021;17:654-655 pubmed publisher |
Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020;11:4528 pubmed publisher |
Xiong H, Wu Y, Cao J, Yang R, Liu Y, Ma J, et al. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect. 2020;9:2105-2113 pubmed publisher |
Chen X, Pan Z, Yue S, Yu F, Zhang J, Yang Y, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. Signal Transduct Target Ther. 2020;5:180 pubmed publisher |
Zost S, Gilchuk P, Chen R, Case J, Reidy J, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020;26:1422-1427 pubmed publisher |
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444-1448 pubmed publisher |
